Amneal Pharmaceuticals (AMRX) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amneal Pharmaceuticals (AMRX) has outperformed Protagonist Therapeutics (PTGX) over the past year, gaining 76.7% versus a gain of 42.2%. Over five years, AMRX leads with a +396.9% price change compared with +265.0% for PTGX. Protagonist Therapeutics is the larger company by market cap ($7.92 billion vs $7.36 billion), about 1.1 times the size, while Amneal Pharmaceuticals is growing revenue faster (+8.0% vs -89.4%).
On valuation, Amneal Pharmaceuticals trades at a lower forward P/E (17.1x vs 348.8x for Protagonist Therapeutics). Amneal Pharmaceuticals converts more of its revenue into profit, with a net margin of 2.4% versus -282.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | PTGX |
|---|---|---|
| Share price | $21.12 | $121.40 |
| Market cap | $7.36B | $7.92B |
| 1-day change | -1.26% | -2.11% |
| YTD return | +67.62% | +39.00% |
| 1-year return | +76.74% | +42.15% |
| 5-year return | +396.94% | +265.00% |
| P/E ratio (TTM) | 52.80 | 25.67 |
| Forward P/E | 17.13 | 348.79 |
| EPS (TTM) | $0.40 | $4.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | $46.02M |
| Revenue growth (YoY) | +8.05% | -89.41% |
| Net income (latest FY) | $72.06M | $-130.15M |
| Gross margin | 36.88% | — |
| Operating margin | 13.05% | -343.63% |
| Net margin | 2.39% | -282.83% |
| 52-week high | $22.13 | $160.81 |
| 52-week low | $11.71 | $77.00 |
| Distance from 52-week high | -4.54% | -24.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +15.01% | +50.21% |
| Average volume | 3.16M | 668.45K |
| Shares outstanding | 348.41M | 65.27M |
| Employees | 8,700 | 149 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRX has outperformed PTGX by 34.6 percentage points over the past year.
- Amneal Pharmaceuticals trades at a higher earnings multiple (52.8x vs 25.7x trailing P/E).
- Amneal Pharmaceuticals is more profitable, keeping 2.4 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
- Amneal Pharmaceuticals grew revenue faster in its latest fiscal year (+8.05% vs -89.41%).
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 149 employees
AMRX vs PTGX FAQ
Which is bigger, Amneal Pharmaceuticals or Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $7.92B compared with $7.36B for Amneal Pharmaceuticals (AMRX).
Which stock has performed better over the past year, AMRX or PTGX?
AMRX returned +76.74% over the past 12 months, compared with +42.15% for PTGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMRX or PTGX?
PTGX has the lower trailing P/E at 25.7, versus 52.8 for AMRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Amneal Pharmaceuticals and Protagonist Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.